3 Euronext Paris Growth Stocks With High Insider Ownership Growing Revenues At 10%
Reviewed by Simply Wall St
As the European markets face heightened investor caution due to escalating Middle East tensions and declining indices, France's CAC 40 Index has seen a notable decline of 3.21%. In this environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In France
| Name | Insider Ownership | Earnings Growth |
| Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 20.6% | 36% |
| VusionGroup (ENXTPA:VU) | 13.4% | 81.7% |
| Icape Holding (ENXTPA:ALICA) | 30.2% | 33.9% |
| Arcure (ENXTPA:ALCUR) | 21.4% | 26.6% |
| La Française de l'Energie (ENXTPA:FDE) | 19.9% | 31.9% |
| S.M.A.I.O (ENXTPA:ALSMA) | 17.4% | 35.2% |
| STIF Société anonyme (ENXTPA:ALSTI) | 16.4% | 28.5% |
| Adocia (ENXTPA:ADOC) | 11.9% | 64% |
| Munic (ENXTPA:ALMUN) | 27.1% | 174.1% |
| MedinCell (ENXTPA:MEDCL) | 15.8% | 93.9% |
Let's review some notable picks from our screened stocks.
Exclusive Networks (ENXTPA:EXN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Exclusive Networks SA is a global cybersecurity specialist focusing on digital infrastructure, with a market cap of €2.14 billion.
Operations: The company's revenue segments are divided into APAC (€480 million), EMEA (€4.19 billion), and Americas (€705 million).
Insider Ownership: 13.1%
Revenue Growth Forecast: 12.2% p.a.
Exclusive Networks, a French cybersecurity firm, is under a proposed buyout by Clayton, Dubilier & Rice and Permira at €2.2 billion (US$2.4 billion), highlighting its high insider ownership with 66.7% held by Permira and founder Olivier Breittmayer. Despite recent earnings declines, the company's revenue is expected to grow 12.2% annually, outpacing the French market's 5.7%. Earnings are projected to rise significantly at 33.5% per year, reflecting robust growth potential amidst strategic transitions.
- Take a closer look at Exclusive Networks' potential here in our earnings growth report.
- Insights from our recent valuation report point to the potential overvaluation of Exclusive Networks shares in the market.
Lectra (ENXTPA:LSS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture markets across Northern Europe, Southern Europe, the Americas, and the Asia Pacific, with a market cap of €1.09 billion.
Operations: The company's revenue segments are comprised of €172.65 million from the Americas and €118.54 million from the Asia-Pacific region.
Insider Ownership: 19.6%
Revenue Growth Forecast: 10.4% p.a.
Lectra, a French company with significant insider ownership, is positioned for strong earnings growth at 29.3% annually over the next three years, surpassing the French market's 12.2%. Despite being valued at 45.8% below its estimated fair value and facing a recent drop from the S&P Global BMI Index, Lectra’s revenue is projected to grow by 10.4% per year—faster than the market average of 5.7%. Recent half-year results showed sales of €262.29 million but a decline in net income to €12.51 million from €14.47 million previously.
- Dive into the specifics of Lectra here with our thorough growth forecast report.
- In light of our recent valuation report, it seems possible that Lectra is trading behind its estimated value.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a pharmaceutical company based in France that specializes in developing long-acting injectables across various therapeutic areas, with a market cap of €446.79 million.
Operations: The company's revenue is derived entirely from its Pharmaceuticals segment, totaling €11.95 million.
Insider Ownership: 15.8%
Revenue Growth Forecast: 46.2% p.a.
MedinCell, with substantial insider ownership, is forecast to achieve profitability within three years and expects revenue growth at 46.2% annually, outpacing the French market's average. Trading significantly below fair value estimates, MedinCell recently joined the S&P Global BMI Index and restructured its governance. A strategic partnership with AbbVie could yield up to $1.9 billion in milestones plus royalties, enhancing its innovative long-acting injectable technology's commercial potential.
- Delve into the full analysis future growth report here for a deeper understanding of MedinCell.
- According our valuation report, there's an indication that MedinCell's share price might be on the cheaper side.
Key Takeaways
- Access the full spectrum of 21 Fast Growing Euronext Paris Companies With High Insider Ownership by clicking on this link.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:MEDCL
MedinCell
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
High growth potential and fair value.
